๎
๎ผ
๎
Milestone Pharmaceuticals Inc
MIST2.070USD
-0.080-3.72%
์ข
๊ฐย 12/22, 16:00๏ผET๏ผ์์ธ๋ 15๋ถ ์ง์ฐ๋ฉ๋๋ค
176.30M์๊ฐ์ด์ก
์์คP/E TTM
๎
์์ธํ ๋ด์ฉ์ Milestone Pharmaceuticals Inc ํ์ฌ
Milestone Pharmaceuticals Inc. is a Canada-based biopharmaceutical company. The Company is focused on the development and commercialization of cardiovascular medicines. Its lead product candidate, etripamil, is a potent rapid-onset calcium channel blocker that the Company designed and is developing as a rapid-onset nasal spray to be administered by patients. The Company is also focused on developing etripamil to treat paroxysmal supraventricular tachycardia, atrial fibrillation, and other cardiovascular indications.
Milestone Pharmaceuticals Inc ์ ๋ณด
๎์ข
๋ชฉ ์ฝ๋ MIST
ํ์ฌ ์ด๋ฆMilestone Pharmaceuticals Inc
์์ฅ์ผMay 09, 2019
CEOOliveto (Joseph)
์ง์ ์33
์ ํOrdinary Share
ํ๊ณ ์ฐ๋ ์ข
๋ฃMay 09
์ฃผ์420-1111 boul. Dr.-Frederik-Philips
๋์MONTREAL
์ฆ๊ถ ๊ฑฐ๋์NASDAQ OMX - NASDAQ BASIC
๊ตญ๊ฐCanada
์ฐํธ ๋ฒํธH4M 2X6
์ ํ15143360444
์น์ฌ์ดํธhttps://www.milestonepharma.com
์ข
๋ชฉ ์ฝ๋ MIST
์์ฅ์ผMay 09, 2019
CEOOliveto (Joseph)
Milestone Pharmaceuticals Inc์ ํ์ฌ ์์์ง
๎์ด๋ฆ
์ด๋ฆ/์ง์
์ง์
์ฃผ์ ๋ณด์
๋ณ๋
Dr. David Bharucha
Dr. David Bharucha
Chief Medical Officer
Chief Medical Officer
78.45K
+212.30%
Mr. Amit Hasija
Mr. Amit Hasija
Chief Financial Officer, Executive Vice President - Corporate Development
Chief Financial Officer, Executive Vice President - Corporate Development
69.20K
+260.35%
Dr. Robert James Wills, Ph.D.
Dr. Robert James Wills, Ph.D.
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
65.00K
+333.33%
Mr. Michael John Tomsicek
Mr. Michael John Tomsicek
Independent Director
Independent Director
15.00K
--
Mr. Stuart Duty
Mr. Stuart Duty
Independent Director
Independent Director
--
--
Mr. Joeseph C. Papa
Mr. Joeseph C. Papa
Independent Director
Independent Director
--
--
Mr. Andrew Saik
Mr. Andrew Saik
Independent Director
Independent Director
--
--
Ms. Lisa M. Giles
Ms. Lisa M. Giles
Independent Director
Independent Director
--
--
Mr. Joseph Oliveto
Mr. Joseph Oliveto
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. Lorenz Muller
Mr. Lorenz Muller
Chief Commercial Officer
Chief Commercial Officer
--
--
๋ ๋ณด๊ธฐ
์ด๋ฆ
์ด๋ฆ/์ง์
์ง์
์ฃผ์ ๋ณด์
๋ณ๋
Dr. David Bharucha
Dr. David Bharucha
Chief Medical Officer
Chief Medical Officer
78.45K
+212.30%
Mr. Amit Hasija
Mr. Amit Hasija
Chief Financial Officer, Executive Vice President - Corporate Development
Chief Financial Officer, Executive Vice President - Corporate Development
69.20K
+260.35%
Dr. Robert James Wills, Ph.D.
Dr. Robert James Wills, Ph.D.
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
65.00K
+333.33%
Mr. Michael John Tomsicek
Mr. Michael John Tomsicek
Independent Director
Independent Director
15.00K
--
Mr. Stuart Duty
Mr. Stuart Duty
Independent Director
Independent Director
--
--
Mr. Joeseph C. Papa
Mr. Joeseph C. Papa
Independent Director
Independent Director
--
--
์์ต ๋ถ์
๊ธฐ์
์ด ์์ง ๊ด๋ จ ๋ฐ์ดํฐ๋ฅผ ๊ณต๊ฐํ์ง ์์์ต๋๋ค.
๊ธฐ์
์ด ์์ง ๊ด๋ จ ๋ฐ์ดํฐ๋ฅผ ๊ณต๊ฐํ์ง ์์์ต๋๋ค.
์ฌ์
๋ณ
์ง์ญ๋ณ
๊ธฐ์
์ด ์์ง ๊ด๋ จ ๋ฐ์ดํฐ๋ฅผ ๊ณต๊ฐํ์ง ์์์ต๋๋ค.
์ฃผ์ ๋ณด์ ํต๊ณ
๋ง์ง๋ง ์
๋ฐ์ดํธ: Mon, Nov 17
๋ง์ง๋ง ์
๋ฐ์ดํธ: Mon, Nov 17
์ฃผ์ฃผ
์ฃผ์ฃผ ์ ํ
์ฃผ์ฃผ
์ฃผ์ฃผ
๋น์จ
Simplify Asset Management Inc
9.34%
Adage Capital Management, L.P.
8.19%
Trails Edge Capital Partners LP
4.50%
OrbiMed Advisors, LLC
3.78%
Morgan Stanley & Co. LLC
3.09%
๊ธฐํ
71.09%
์ฃผ์ฃผ
์ฃผ์ฃผ
๋น์จ
Simplify Asset Management Inc
9.34%
Adage Capital Management, L.P.
8.19%
Trails Edge Capital Partners LP
4.50%
OrbiMed Advisors, LLC
3.78%
Morgan Stanley & Co. LLC
3.09%
๊ธฐํ
71.09%
์ฃผ์ฃผ ์ ํ
์ฃผ์ฃผ
๋น์จ
Investment Advisor
16.23%
Hedge Fund
14.25%
Research Firm
5.04%
Investment Advisor/Hedge Fund
3.94%
Private Equity
3.78%
Individual Investor
3.57%
Venture Capital
1.22%
Family Office
1.17%
Bank and Trust
0.02%
๊ธฐํ
50.77%
๊ธฐ๊ด ์ฃผ์ ๋ณด์
๎๋ง์ง๋ง ์
๋ฐ์ดํธ: Wed, Oct 1
๋ง์ง๋ง ์
๋ฐ์ดํธ: Wed, Oct 1
๋ณด๊ณ ๊ธฐ๊ฐ
๊ธฐ๊ด ์
๋ณด์ ์ฃผ์
๋น์จ
๋ณ๋
2025Q3
99
19.38M
22.80%
-5.64M
2025Q2
99
14.54M
18.86%
-15.65M
2025Q1
102
12.26M
22.94%
-17.24M
2024Q4
99
25.17M
47.19%
-9.38M
2024Q3
113
29.31M
55.02%
-13.44M
2024Q2
115
30.81M
57.87%
-11.80M
2024Q1
116
31.96M
60.43%
+3.19M
2023Q4
112
18.49M
55.02%
-13.59M
2023Q3
109
20.24M
60.32%
-12.06M
2023Q2
108
21.35M
63.87%
-11.78M
๋ ๋ณด๊ธฐ
์ฃผ์ฃผ ํ๋
๎์ด๋ฆ
๋ณด์ ์ฃผ์
๋น์จ
๋ณ๋
Chg %
๋ ์ง
Simplify Asset Management Inc
990.00K
1.16%
+140.00K
+16.47%
Jun 30, 2025
Trails Edge Capital Partners LP
5.33M
6.27%
+5.33M
--
Jul 14, 2025
Morgan Stanley & Co. LLC
817.82K
0.96%
-148.10K
-15.33%
Jun 30, 2025
Oliveto (Joseph Gerard)
2.51M
2.95%
+66.67K
+2.73%
Jul 11, 2025
RTW Investments L.P.
2.51M
2.95%
--
--
Jun 30, 2025
Propel Bio Management, LLC
1.79M
2.11%
+340.00K
+23.42%
Jun 30, 2025
๋ ๋ณด๊ธฐ
๊ด๋ จ ETF
๎๋ง์ง๋ง ์
๋ฐ์ดํธ: Tue, Dec 2
๋ง์ง๋ง ์
๋ฐ์ดํธ: Tue, Dec 2
์ด๋ฆ
๋น์จ
Simplify Propel Opportunities ETF
8.04%
SPDR S&P International Small Cap ETF
0.01%
Avantis US Small Cap Equity ETF
0%
Simplify Propel Opportunities ETF
๋น์จ8.04%
SPDR S&P International Small Cap ETF
๋น์จ0.01%
Avantis US Small Cap Equity ETF
๋น์จ0%
์ฃผ์ ๋ฐฐ๋น๊ธ
๎์ง๋ 5๋
๋์ ์ด
0.00
USD์ ๋ฐฐ๋น๊ธ์ด ๋ถ๋ฐฐ๋์์ต๋๋ค.
๋ ์ง
๋ฐฐ๋น๊ธ
๊ธฐ์ค์ผ
์ง๊ธ์ผ
๋ฐฐ๋น๋ฝ์ผ
๋ฐ์ดํฐ ์์
์ฃผ์ ๋ถํ
๎๋ ์ง
์ ํ
๋น์จ
๋ฐ์ดํฐ ์์
๋ ์ง
์ ํ
๋น์จ
๋ฐ์ดํฐ ์์
์์ฃผ ๋ฌป๋ ์ง๋ฌธ
Milestone Pharmaceuticals Inc์ ์์ 5๋ ์ฃผ์ฃผ๋ ๋๊ตฌ์ธ๊ฐ์?
๎Milestone Pharmaceuticals Inc์ ์์ 5๋ ์ฃผ์ฃผ๋ ๋ค์๊ณผ ๊ฐ์ต๋๋ค:
Simplify Asset Management Inc๋ 990.00K์ฃผ์ ์ฃผ์์ ๋ณด์ ํ๊ณ ์์ผ๋ฉฐ, ์ ์ฒด ์ฃผ์์ 1.16%๋ฅผ ์ฐจ์งํฉ๋๋ค.
Trails Edge Capital Partners LP๋ 5.33M์ฃผ์ ์ฃผ์์ ๋ณด์ ํ๊ณ ์์ผ๋ฉฐ, ์ ์ฒด ์ฃผ์์ 6.27%๋ฅผ ์ฐจ์งํฉ๋๋ค.
Morgan Stanley & Co. LLC๋ 817.82K์ฃผ์ ์ฃผ์์ ๋ณด์ ํ๊ณ ์์ผ๋ฉฐ, ์ ์ฒด ์ฃผ์์ 0.96%๋ฅผ ์ฐจ์งํฉ๋๋ค.
Oliveto (Joseph Gerard)๋ 2.51M์ฃผ์ ์ฃผ์์ ๋ณด์ ํ๊ณ ์์ผ๋ฉฐ, ์ ์ฒด ์ฃผ์์ 2.95%๋ฅผ ์ฐจ์งํฉ๋๋ค.
RTW Investments L.P.๋ 2.51M์ฃผ์ ์ฃผ์์ ๋ณด์ ํ๊ณ ์์ผ๋ฉฐ, ์ ์ฒด ์ฃผ์์ 2.95%๋ฅผ ์ฐจ์งํฉ๋๋ค.
Simplify Asset Management Inc๋ 990.00K์ฃผ์ ์ฃผ์์ ๋ณด์ ํ๊ณ ์์ผ๋ฉฐ, ์ ์ฒด ์ฃผ์์ 1.16%๋ฅผ ์ฐจ์งํฉ๋๋ค.
Trails Edge Capital Partners LP๋ 5.33M์ฃผ์ ์ฃผ์์ ๋ณด์ ํ๊ณ ์์ผ๋ฉฐ, ์ ์ฒด ์ฃผ์์ 6.27%๋ฅผ ์ฐจ์งํฉ๋๋ค.
Morgan Stanley & Co. LLC๋ 817.82K์ฃผ์ ์ฃผ์์ ๋ณด์ ํ๊ณ ์์ผ๋ฉฐ, ์ ์ฒด ์ฃผ์์ 0.96%๋ฅผ ์ฐจ์งํฉ๋๋ค.
Oliveto (Joseph Gerard)๋ 2.51M์ฃผ์ ์ฃผ์์ ๋ณด์ ํ๊ณ ์์ผ๋ฉฐ, ์ ์ฒด ์ฃผ์์ 2.95%๋ฅผ ์ฐจ์งํฉ๋๋ค.
RTW Investments L.P.๋ 2.51M์ฃผ์ ์ฃผ์์ ๋ณด์ ํ๊ณ ์์ผ๋ฉฐ, ์ ์ฒด ์ฃผ์์ 2.95%๋ฅผ ์ฐจ์งํฉ๋๋ค.
Milestone Pharmaceuticals Inc์ ์์ 3๋ ์ฃผ์ฃผ ์ ํ์ ๋ฌด์์ธ๊ฐ์?
๎Milestone Pharmaceuticals Inc์ ์ฃผ์ ์ฃผ์ฃผ ์ ํ ์์ 3๊ฐ์ง๋
Simplify Asset Management Inc
Adage Capital Management, L.P.
Trails Edge Capital Partners LP์ ๋๋ค.
Simplify Asset Management Inc
Adage Capital Management, L.P.
Trails Edge Capital Partners LP์ ๋๋ค.
Milestone Pharmaceuticals Inc(MIST)์ ์ฃผ์์ ๋ณด์ ํ ๊ธฐ๊ด์ ๋ช ๊ฐ์ ๋๊น?
๎2025Q3 ๊ธฐ์ค์ผ๋ก, Milestone Pharmaceuticals Inc์ ์ฃผ์์ ๋ณด์ ํ ๊ธฐ๊ด์ ์ด 99๊ณณ์ด๋ฉฐ, ์ด๋ค์ด ๋ณด์ ํ ์ฃผ์์ ์ด ๊ฐ์น๋ ์ฝ 19.38M๋ก ์ ์ฒด ๋ฐํ ์ฃผ์์ 22.80%๋ฅผ ์ฐจ์งํฉ๋๋ค. ์ด๋ 2025Q2 ๋๋น 3.94% ์ฆ๊ฐํ ์์น์
๋๋ค.
Milestone Pharmaceuticals Inc์ ์ต๋ ์์ต์์ ๋ฌด์์ธ๊ฐ์?
๎-- ๊ธฐ์ค, Milestone Pharmaceuticals Inc์ -- ๋ถ๋ฌธ์ด ๊ฐ์ฅ ๋์ ๋งค์ถ์ ๊ธฐ๋กํ์ผ๋ฉฐ, ๊ธ์ก์ --๋ก ์ ์ฒด ๋งค์ถ์ --%๋ฅผ ์ฐจ์งํ์ต๋๋ค.
